New hope for tough blood cancers? early trial launches for ZZSW-01
NCT ID NCT07240974
First seen Nov 21, 2025 · Last updated May 14, 2026 · Updated 20 times
Summary
This early-phase study tests a new drug called ZZSW-01 in 6 adults with certain blood cancers (B-cell malignancies) that have returned or not responded to prior treatments. The main goals are to check safety, find the right dose, and see if the drug shrinks tumors. Participants will receive the drug by injection and be closely monitored for side effects like cytokine release syndrome.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED/REFRACTORY B-CELL MALIGNANCIES are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
RECRUITINGWuhan, 430022, China
Conditions
Explore the condition pages connected to this study.